Hep C Discussion Forum

Members Login
    Remember Me  
Please log in to join the chat!
Post Info TOPIC: About "Hepatiq", Dr. Hoefs QLSS hepatic function technique VS fibrosis measurements


Status: Offline
Posts: 3249
About "Hepatiq", Dr. Hoefs QLSS hepatic function technique VS fibrosis measurements

This company has recently been promoting it's "product" as being FDA approved - their developed "method", their "product" (a sort of "scan/multi-level assessment/analysis") is being touted as a better, fuller, more informative way to assess hepatic "function", than other assesment methods. "QLSS" (Quantitative Liver Spleen Scan) technique of hepatic "function" analysis encompasses at least 3 components, and is compared to other methods that rely more heavily on "fibrosis" level measurements. To get a handle on the intricacies of their testing method(s) they employ, you have to suss all of the old work/publications going back to 2008, 2010, 2014 - Dr. Hoefs work on this QLSS technique. Tiring but interesting!

Here are some links to peruse (about the company/website) and some publications/articles relating to Dr. Hoefs work (to try to get acqauinted with their ideas, arguments and the processes they employ, which they claim is better than what we can be doing with other assessment tools/methods):






Quantitative Hepatic Function Predicts Outcomes of Chronic Liver ...



  1. Quantitative Liver Function Tests Improve the Prediction of Clinical Outcomes in Chronic Hepatitis C: Results From the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Gregory T. Everson, Mitchell L. Shiffman, John C. Hoefs, et. al.; HEPATOLOGY 2012; volume 55: pages 1019-1029.
  2. Functional Elements Associated with Hepatic Regeneration in Living Donors after Right Hepatic Lobectomy.  Gregory T. Everson, John C. Hoefs, Claus U. Niemann, Kim M Olthoff, Robert Dupuis, Shannon Lauriski, Andrea Herman, Norah Milne, Brenda W. Gillespie, Nathan P. Goodrich and James E. Everhart; LIVER TRANSPLANTATION, Vol. 19, No. 3, 2013.
  3. Physiologic Staging in alcoholic Liver Disease Predicts Death and Monitors Recovery, John C. Hoefs, Poster, EASL, The International Liver Congress, 2017.
  4. Steatohepatitis: Differential Features on Quantitative Liver-Spleen Scan (QLSS), John C. Hoefs, Poster, EASL, The International Liver Congress, 2017.
  5. Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial; http://www.haltctrial.org/overview.html.
  6. Adult to Adult Living Donor Liver Transplantation Cohort (A2ALL) studies; http://www.nih-a2all.org/default.asp .
  7. Hoefs JC:  Portal Hypertension.  In:  Gitnick G, ed., Principles and Practice of Gastroenterology and Hepatology.  New York: Elsevier, 1988.  Revised 1993, 1994.
  8. Hoefs JC, Chen PT, Lizotte P.  Non-invasive Evaluation of Liver disease Severity. Clin of Liver Dis Dec 2006; 10: 535-562.
  9. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, et al. The Spectrum of Hepatic Functional Impairment in Patients with Fibrosis and Compensated Cirrhosis Due to Chronic Hepatitis C: Results from the HALT-C Trial. Alimentary Pharmacology & Therapeutics 2008 (accepted).
  10. Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC. Noninvasive Measurement Of Portal-Systemic Shunting In Patients With Fibrosis Or Cirrhosis Due To Chronic Hepatitis C: The Minimal Model For Measuring Cholate Clearances And Shunt In Man.  Alimentary Pharmacology & Therapeutics 2007; 26:401-410
  11. Hoefs JC, Chen PT, Lizotte P.  Non-invasive Evaluation of Liver disease Severity. Clin of Liver Dis Dec 2006; 10: 535-562.
  12. Hoefs JC, Wang F, Kanel G, Braunstein P. The liver-spleen scan as a quantitative liver function test: Correlation with liver severity at peritoneoscopy.  Hepatology. 1995; 22:1113-1121.
  13. Hoefs JC, Wang F, Kanel G. Functional measurement of the non-fibrotic hepatic mass in cirrhotic patient. Am J Gastroenterology. 1997; 92:2054-2058.
  14. Hoefs JC, Green G, Reynolds TB, Sakimura I:  Mechanism for the Abnormal liver scan in acute alcoholic liver injury.  Amer Jour of Gastroenterology 1984; 79(12):950-958.
  15. Hoefs J, Chang K, Wang F, Kanel G, Morgan T, Braunstein P. The perfused Kupffer cell mass: Correlation with histology and severity of CLD. Dig Dis Sci. 1995; 40:552-560.
  16. Hoefs JC, Sheikh M, Guererro HJ Milne N:  Factors affecting the quantitative liver spleen scan in normal individuals.  Digestive Diseases and Sciences  2005; 50:283-9
  17. Hoefs J.C., Wang F., Lilien D., Walker B., Kanel B.  A novel, simple method of functional spleen volume calculation by liver-spleen scan.   J Nucl Med. 1999;40:1745-55.
  18. Hoefs JC; Everson GT; Shiffman ML; Morgan TR; Naishadham D; Wright, EL. Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver Disease Severity in Baseline HALT-C Patients with Moderate Fibrosis or Cirrhosis Hepatology: Poster 2006
  19. Everson E, Schiffman M, Hoefs J, et al. Quantitative liver function tests predict sustained virologic response to retreatment with peginterferon alfa-2a plus ribavirin:  results of the lead-in phase of the halt-C trial. Hepatology 2004; 40:A348;p 313A.
  20. Hoefs J, Herron T, Vikramjit A, Lizotte P, Shieh, Y. Enhanced Detection of Cirrhosis by Novel Intra-hepatic Count Distribution Measures on Quantitative Liver-Spleen Scan (QLSS) Gastro 2007:   (Oral Presentation at the Digestive Disease Week 5/07)
  21. Hoefs JC, Jonas GM, Sarfeh IJ. Diagnosis and hemodynamic assessment of portal hypertension. Surg Clin North Am 1990;70:269-89.
  22. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M.  Sepsis in Cirrhosis - Report on the 7th Meeting of the International Ascites Club.  Gut  2005:  54(5):718-25.
  23. Hoefs JC: Spontaneous Bacterial Peritonitis: Prevention and Therapy. Hepatology 1990;12:776-781.
  24. Hoefs JC, Runyon B:  Spontaneous Bacterial Peritonitis.  Disease-A-Month 31 (9):3-48, 1985.

-- Edited by Canuck on Saturday 18th of November 2017 02:05:30 AM


HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 64 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.



Page 1 of 1  sorted by
Quick Reply

Please log in to post quick replies.

Legal Disclaimer: